<DOC>
	<DOCNO>NCT00986518</DOCNO>
	<brief_summary>T regulatory lymphocyte show partly responsible immune tolerance cancer cell . In respect cell oppose mount efficacious immune response need cure cancer . To treat advanced metastatic colorectal cancer , investigator propose immunotherapy consist autologous lymphocyte infusion deplete T-regulatory cell , associate 5-day prior lymphoid-ablative chemotherapy associate cyclophosphamide ( day 1 &amp; 2 ) fludarabine ( day 1 5 ) . To administer treatment monitor chemotherapy safety , patient hospitalize 3 week complete recovery chemotherapy . Patients followed-up ambulatory 9 month time assess tumor size compute tomography ( CT ) - scan ( primary criterion ) .</brief_summary>
	<brief_title>T Regulatory Lymphocytes ( Treg ) Depletion Cancer Treatment Efficacy Safety Study</brief_title>
	<detailed_description>The primary goal propose clinical trial eliminate cancer tumor use autologous cell therapy aim mount efficient immune anti-tumor response selectively deplete regulatory T-cell control amount time . This strategy test patient hepatic metastasis colorectal eligible surgery . This open-label single cohort phase I-II therapeutic trial . Patients hepatic metastasis primary colorectal cancer , eligible surgery relapse conventional chemotherapy and/or target therapy , include . Following patient inclusion : 1 . A lymphapheresis perform D-15 subject cell sort /purification regulatory T cell one hand T lymphocytes deplete regulatory T cell ( effector T-cells ) , subsequently frozen store ( The procedure ex vivo regulatory T cell depletion validate previous study - AFSSAPS- TC 192 ) ; 2 . A lymphoid-ablative chemotherapy ( cyclophosphamide + fludarabine ) perform D1 D5 , 3 . Autologous effector T-cells administration perform D7 . Efficacy assess tumor size change . Change tumor size assess CTscans ( RECIST criterion ) , MRIs ( functional criterion follow injection : DCEMRI diffusion MRI ass change cellularity tumor necrosis morphological criterion RECIST ) , sonography contrast injection ( assess vascular microcirculation ) . Assessments do prior lymphoid-ablation monthly 9 month . Safety systematically assess daily in-patient period use World Health Organisation - Common Toxicity Criteria ( WHO-CTC ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Colon rectal adenocarcinoma histologically proven ; Hepatic lung metastasis ( least one size &gt; 1cm CTscan ) ; Not eligible surgery ; Prior treatment fluoropyrimidines , CPT11 , oxaliplatine EGFR antibody ( Cetuximab ou Panitumumab ) ± bevacizumab ; When tumor mutate Kras , prior treatment EGFR antibodies mandatory ; No local recurrence ( CTscan , sonogram and/or colonoscopy ) ; Karnofsky index &gt; 70 PS 0 1 ; ASA Score &lt; 3 ; Absence chronic hepatopathy ; Lab test : WBC : neutrophil &gt; 2.0 109 / l , lymphocytes &gt; 1.5 109 / l ; creatinine &lt; 1.5 x ULN clearance ≥ 60 ml/min ; AST et ALT &lt; 5 x ULN , alkaline phosphatase &lt; 3 x ULN ; LDH &lt; 3 x ULN ; negative Coombs test ; Signed informed consent . Peritoneal carcinosis CTscan , MRI PETscan ; Contraindication MRI ; Patient know allergy iodinate contrast agent , gadolinium Sulfate Hexafluoron ; Presence metastasis sit lung liver ; Documented history autoimmune disease and/ progress disease ; Infection whatever site ; Documented history allo autograft ; Undernutrition , BMI &lt; 18 ; History cancer &lt; 5 year ( exclude cancer situ cervix basocellular tumor skin ) progress disease ; Women child bear age without contraception , pregnant breast feeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Advanced Colorectal Cancer</keyword>
	<keyword>Hepatic and/or lung metastasis</keyword>
	<keyword>Adaptive autologous cell immunotherapy</keyword>
	<keyword>T- regulatory lymphocyte depletion</keyword>
	<keyword>Neo-adjuvant reduced intensity chemotherapeutic conditioning</keyword>
</DOC>